Mostrar el registro sencillo del ítem

dc.contributor.authorDa Silva Candal, Andrés Alexander
dc.contributor.authorArgibay González, Bárbara
dc.contributor.authorIglesias Rey, Ramón
dc.contributor.authorVargas, Zulema
dc.contributor.authorVieites Prado, Alba
dc.contributor.authorLópez Arias, Esteban 
dc.contributor.authorRodriguez Castro, Emillio Francisco 
dc.contributor.authorLópez Dequidt, Iria Alejandra 
dc.contributor.authorRodríguez Yáñez, Manuel 
dc.contributor.authorPiñeiro, Yolanda 
dc.contributor.authorSobrino Moreiras, Tomas 
dc.contributor.authorCampos Pérez, Francisco 
dc.contributor.authorRivas, José
dc.contributor.authorCastillo Sánchez, José 
dc.date.accessioned2017-10-09T11:06:54Z
dc.date.available2017-10-09T11:06:54Z
dc.date.issued2017-04-11
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/?term=vectorized+nanodelivery+systemses
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387212/es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/9702
dc.description.abstractNeurological diseases of diverse aetiologies have significant effects on the quality of life of patients. The limited self-repairing capacity of the brain is considered to be the origin of the irreversible and progressive nature of many neurological diseases. Therefore, neuroprotection is an important goal shared by many clinical neurologists and neuroscientists. In this review, we discuss the main obstacles that have prevented the implementation of experimental neuroprotective strategies in humans and propose alternative avenues for the use of neuroprotection as a feasible therapeutic approach. Special attention is devoted to nanotechnology, which is a new approach for developing highly specific and localized biomedical solutions for the study of the multiple mechanisms involved in stroke. Nanotechnology is contributing to personalized neuroprotection by allowing us to identify mechanisms, determine optimal therapeutic windows, and protect patients from brain damage. In summary, multiple aspects of these new players in biomedicine should be considered in future in vivo and in vitro studies with the aim of improving their applicability to clinical studies.es
dc.description.sponsorshipThis project was partially supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2011-30517 and SAF2014-56336-R), Xuntade Galicia (Consellería de Educación: GRC2014/027, and Axencia Galegade Innovación), Instituto de Salud Carlos III (PI13/00292 and PI14/01879), Spanish Research Network on Cerebrovascular Diseases RETICS-INVICTUS (RD16/0019), and by the European Union FEDER program. This study was also co-funded by the POCTEP (Operational Programme for Cross-border Cooperation Spain–Portugal) program (0681_INVENNTA_1_E) and co-financed by the ERDF (European Regional Development Fund). T. Sobrino (CP12/03121) and F. Campos (CP14/00154) are recipients of research contracts from Miguel Servet Program of Instituto de Salud Carlos III. Likewise, A. Vieites-Prado is the recipient of a FPI fellowship (BES-2012-056027) from the Spanish Ministry of Economy and Competitivenesses
dc.description.sponsorshipMinisterio de Economía y Competitividad (España) (SAF2011-30517 y SAF2014-56336-R)es
dc.description.sponsorshipXunta de Galicia. Consellería de Educaciónes
dc.description.sponsorshipXunta de Galicia. Axencia Galega de Innovaciónes
dc.description.sponsorshipInstituto de Salud Carlos IIIes
dc.description.sponsorshipRed de Enfermedades Vasculares Cerebrales RETICS-INVICTUSes
dc.description.sponsorshipFondo Europeo de Desarrollo Regional (FEDER)es
dc.description.sponsorshipPrograma cooperación transfronteriza España - Portugal (POCTEP)es
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshIschemia*
dc.subject.meshNeuroprotective Agents*
dc.subject.meshTime Factors*
dc.subject.meshDrug Delivery Systems*
dc.subject.meshNanoparticles*
dc.subject.meshBrain Ischemia*
dc.subject.meshStroke*
dc.titleVectorized nanodelivery systems for ischemic stroke: a concept and a needes
dc.typeArtigoes
dc.identifier.doi10.1186/s12951-017-0264-7
dc.identifier.essn1477-3155
dc.identifier.pmid28399863
dc.issue.number1es
dc.journal.titleJournal of nanobiotechnologyes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Neuroloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.page.initial30es
dc.relation.projectIDMinisterio de Economía y Competitividad (España) /SAF2011-30517es
dc.relation.projectIDMinisterio de Economía y Competitividad (España)/ SAF2014-56336-R)es
dc.relation.projectIDXunta de Galicia. Consellería de Educación/GRC2014/027es
dc.relation.projectIDInstituto de Salud Carlos III/PI13/00292es
dc.relation.projectIDInstituto de Salud Carlos III/PI14/01879es
dc.relation.projectIDRed de Enfermedades Vasculares Cerebrales RETICS-INVICTUS (RD16/0019)es
dc.relation.projectIDPrograma cooperación transfronteriza España - Portugal (POCTEP)/0681_INVENNTA_1_Ees
dc.relation.publisherversionhttps://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-017-0264-7es
dc.rights.accessRightsopenAccesses
dc.subject.cie10Ataques de isquemia cerebral transitoria y síndromes afines es
dc.subject.decsisquemia*
dc.subject.decsisquemia cerebral*
dc.subject.decsfármacos neuroprotectores*
dc.subject.decsaccidente cerebrovascular*
dc.subject.decssistemas de liberación de medicamentos*
dc.subject.decsfactores de tiempo*
dc.subject.decsnanopartículas*
dc.subject.keywordisquemiaes
dc.subject.keywordderrame cerebrales
dc.subject.keywordnanopartículases
dc.typefidesArtigo Científico (inclue Orixinal, Orixinal breve, Revisión Sistemática e Meta-análisis)es
dc.typesophosArtículo de Revisiónes
dc.volume.number15es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional